Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) will host a conference call on February 26, 2026 at 8:00 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and business updates.

Investors may join via webcast or teleconference; a replay will be available for approximately 90 days on the company’s Events page.

News Market Reaction

+0.16%

1 alert

+0.16% News Effect

On the day this news was published, NTLA gained 0.16%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: February 26, 2026 Conference time: 8 a.m. ET U.S. dial-in: 1-833-316-0545 +2 more

5 metrics

Conference date February 26, 2026 Scheduled earnings and business update call

Conference time 8 a.m. ET Start time for Q4 and full-year 2025 call

U.S. dial-in 1-833-316-0545 Domestic teleconference access number

International dial-in 1-412-317-5726 International teleconference access number

Replay duration 90 days Replay availability on the company’s website

Market Reality Check

Price: $13.04 Vol: Volume 2,516,958 vs 20-da...

low vol

$13.04 Last Close

Volume Volume 2,516,958 vs 20-day average 5,447,352 (relative volume 0.46x). low

Technical Trading slightly above 200-day MA ($12.48 vs $12.03) ahead of the call.

Peers on Argus

NTLA was up 2.13% pre-announcement with mixed peer moves: RCUS up 2.37%, ELVN up...

1 Up

NTLA was up 2.13% pre-announcement with mixed peer moves: RCUS up 2.37%, ELVN up 1.46%, DNTH down 2.49%, ZYME slightly down and TRML flat, suggesting stock-specific positioning rather than a broad sector move.

Previous Conferences,earnings Reports

5 past events · Latest: Jul 31 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jul 31	Earnings call scheduling	Neutral	-5.6%	Announced Q2 2025 earnings call date and access details.
May 01	Earnings call scheduling	Neutral	-2.6%	Announced Q1 2025 earnings call timing and participation info.
Feb 20	Earnings call scheduling	Neutral	-0.2%	Set date for Q4 and full-year 2024 results call.
Aug 01	Earnings call scheduling	Neutral	-4.1%	Announced Q2 2024 earnings and updates conference call.
May 02	Earnings call scheduling	Neutral	+3.4%	Outlined Q1 2024 results call focused on CRISPR programs.

Pattern Detected

Similar conference/earnings-call scheduling headlines have historically been followed by an average move of -1.82%, often skewing slightly negative despite the neutral nature of the news.

Recent Company History

Over the past two years, NTLA has repeatedly announced earnings and business update conference calls, including events on May 2, 2024, Aug 1, 2024, Feb 20, 2025, May 1, 2025, and Jul 31, 2025. These releases were largely procedural, outlining dates, times, and access details for quarterly and annual results. Despite their neutral content, share reactions around these announcements have averaged -1.82%, with several instances of modest single-day declines.

Historical Comparison

-1.8% avg move · In the past, NTLA’s conference-call scheduling headlines under the same tag averaged a -1.82% move. ...

conferences,earnings

-1.8%

Average Historical Move conferences,earnings

In the past, NTLA’s conference-call scheduling headlines under the same tag averaged a -1.82% move. Today’s pre-news gain of 2.13% contrasts with that pattern, suggesting positioning ahead of the event rather than the announcement itself.

The company has consistently issued conference-call notices for quarterly and annual results from 2024 through 2025, maintaining a regular cadence of updates on financial performance and operational progress tied to its CRISPR-based pipeline.

Market Pulse Summary

This announcement sets a clear date—February 26, 2026 at 8 a.m. ET—for Intellia’s discussion of four...

Analysis

This announcement sets a clear date—February 26, 2026 at 8 a.m. ET—for Intellia’s discussion of fourth quarter and full-year 2025 results and business updates. Historically, similar conference-call notices under this tag have averaged a modest -1.82% move, suggesting they are viewed as procedural. With elevated short interest of 35.88% and 13.73 days to cover, upcoming actual earnings details, pipeline updates, and any guidance changes will be key metrics to watch.

Key Terms

clinical-stage, gene editing, CRISPR-based therapies, webcast, +1 more

5 terms

clinical-stage medical

"a leading clinical-stage gene editing company focused on revolutionizing medicine"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

gene editing medical

"a leading clinical-stage gene editing company focused on revolutionizing medicine"

Gene editing is a set of laboratory techniques that change the DNA inside living cells to add, remove, or alter specific genes, like using precise 'cut-and-paste' tools to edit an instruction manual for a living organism. It matters to investors because successful edits can produce new therapies, improve agricultural products, or create commercial advantages; progress, safety, regulatory approvals, and patent control all affect a company’s value and risk profile.

CRISPR-based therapies medical

"company focused on revolutionizing medicine with CRISPR-based therapies"

CRISPR-based therapies are medical treatments that use a precise, programmable tool to find and change specific bits of a patient’s DNA, like using molecular scissors to edit a line in a recipe. They matter to investors because successful edits can potentially cure inherited or hard-to-treat diseases, offering high commercial upside, but they also carry long development timelines, regulatory hurdles, safety uncertainties, and manufacturing and intellectual-property risks that affect valuation.

webcast technical

"To join a webcast of the call, please visit this link."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

teleconference technical

"To join the teleconference, U.S. callers should dial 1-833-316-0545"

A teleconference is a live meeting held over phone or internet where company leaders, analysts, and investors join from different locations to share information and answer questions. For investors it matters because these sessions reveal management’s plans, performance details and tone—similar to listening in on a boardroom briefing—so they can reassess a company’s outlook and make better buy, hold, or sell decisions.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and business updates.

To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.

A replay of the call will be available for approximately 90 days on the Events page in the Investors & Media section of Intellia’s website, www.intelliatx.com.

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.

Intellia Contact:

Jason Fredette
Vice President, Investor Relations and Corporate Communications
jason.fredette@intelliatx.com

This press release was published by a CLEAR® Verified individual.

FAQ

When is Intellia Therapeutics (NTLA) holding its Q4 and full-year 2025 results call?

The call is scheduled for February 26, 2026 at 8:00 a.m. ET. According to the company, the discussion will cover fourth-quarter and full-year 2025 financial results and business updates with a subsequent replay available for about 90 days.

How can investors access the Intellia Therapeutics (NTLA) earnings webcast on February 26, 2026?

Investors can join the live webcast via the company’s Events page on its investor website. According to the company, the webcast link will host the live audio and a replay will be posted for approximately 90 days.

What phone numbers should I use to join Intellia Therapeutics (NTLA) teleconference on Feb 26, 2026?

U.S. callers should dial 1-833-316-0545; international callers should dial 1-412-317-5726. According to the company, callers should dial about five minutes early and request connection to the Intellia Therapeutics conference call.

Will there be a replay of the Intellia Therapeutics (NTLA) February 26, 2026 call and where is it available?

Yes. A replay will be available for approximately 90 days on the company’s Events page in the Investors & Media section. According to the company, the replay will include the full call audio after the live event concludes.

What topics will Intellia Therapeutics (NTLA) cover in the February 26, 2026 call?

The company will discuss fourth-quarter and full-year 2025 financial results and business updates. According to the company, management will present results and provide updates on corporate and clinical developments relevant to investors.